| Document |
Document Title |
|
WO/2024/081739A2 |
The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound an...
|
|
WO/2024/074641A1 |
The present invention relates to a method for preparing of an amide of the formula (I-1) or a diamide of the formula (I-2) where the variables areas defined in the claims and the description, by reacting an ester with an aromatic or hete...
|
|
WO/2024/075535A1 |
In the present invention, there is employed a resist composition having, as a base resin, a polymer compound that has constituent units derived from a compound expressed by general formula (a0−m). In the formula, W is a polymerizable-g...
|
|
WO/2024/071392A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2(-CH2-R3-CH2-R2)x-CH2-R4 (In the formula, x represents an integer of 1 or 2; R2 represents a perfluoropolyether chain; R3 is represented by formula...
|
|
WO/2024/071399A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (x is 1 or 2. R2 is a perfluoropolyether chain. R3 is represented by formula (2). R1 and R4 are terminal groups having 1-5...
|
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
|
WO/2024/065043A1 |
Provided are lipids and nanoparticles containing such lipids and a cargo molecule, such as nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The li...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/050715A1 |
Provided in the present application are amide compounds having amino groups on both ends, having general formula (I), in which A and B are independently selected from substituted or unsubstituted C1-C18 alkylene groups, C2-C18 alkenylene...
|
|
WO/2024/054321A1 |
Non-triazole compounds are provided that can be effective to inhibit corrosion of a corrodible metal surface in an aqueous system. The non-triazole compounds show comparable or better corrosion inhibition as compared to conventional tria...
|
|
WO/2024/050108A2 |
Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising one or more compounds that promotes interferon, e.g., interferon g...
|
|
WO/2024/048438A1 |
The present invention addresses the problem of providing: a diastereomer preparation method whereby it becomes possible to produce a desired diastereomer from a diastereomer mixture with high efficiency; and a solid-phase photosensitizer...
|
|
WO/2024/040745A1 |
The present application provides an amide compound containing iodo aryl or iodo heteroaryl, and a preparation method therefor and a use thereof. The amide compound containing iodo aryl or iodo heteroaryl can be used for preparing an X-ra...
|
|
WO/2024/044728A1 |
The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various acti...
|
|
WO/2024/040091A1 |
Embodiments of the present disclosure relate to lipid-PEGylated solid support and phosphoramidites derivatives, methods for preparing the same, and their uses in the delivery of oligonucleotide drugs to the cellular targets.
|
|
WO/2024/040182A1 |
Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine or a pharmaceutically acceptable thereof to treat cancers and precancer lesions, including cancers and precancer lesions associated with papilloma virus ...
|
|
WO/2024/032774A1 |
Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has the structural characteristics of formula (I).
|
|
WO/2024/031970A1 |
The present invention relates to a compound having a chemical formula (I), and further relates to a preparation method therefor and use thereof. Pharmacological experiment results show that the compound of the present invention has excel...
|
|
WO/2024/033479A1 |
The application relates to compounds of formula (B1A), (B1B), (B1C) or a salt, a solvate, a hydrate, a polymorph, a tautomer, a racemate or a stereoisomer thereof, to pharmaceutical compositions comprising such a compound, and to the com...
|
|
WO/2024/030627A1 |
Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd, and n are described herein. Also provided herein are compositions comprising compounds of Formula ...
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/024781A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (x represents an integer of 1 or 2, R2 represents a perfluoropolyether chain, at least one of the x-number of R3 is repres...
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2024/013445A1 |
The present invention relates to a compound of formula (1), wherein the variables R, X, l, R 1, R 2, A, n and R 3 are as defined in the description. The invention also relates to the use of the compound of formula (1) as a surfactant.
|
|
WO/2024/007851A1 |
A catalyst for amide synthesis and preparation and use thereof are disclosed. The catalyst is a thio or seleno pyranodipyrimidine compound and has a simple and novel structure, high catalytic efficiency, and good atom economy. The cataly...
|
|
WO/2024/007722A1 |
Provided is a compound of Formula (I) : Besides, provided is a pharmaceutical composition comprising the above compound and their use for preventing or treating cocaine addiction, reducing the likelihood of a relapse of cocaine addiction...
|
|
WO/2024/002746A1 |
The invention relates to compositions comprising at least on self tanning agent and certain sphingolipids and/or certain sphingoid bases.
|
|
WO/2023/250318A1 |
Anthraquinone analogs that have anticancer properties are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating ...
|
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
|
WO/2023/250486A1 |
Disclosed herein are furan fatty acid synthetic compounds and furan fatty acid – amino acid conjugates.
|
|
WO/2023/250059A1 |
Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourett...
|
|
WO/2023/240790A1 |
Disclosed in the present invention is a method for preparing an N-formyl amide compound under the catalysis of visible light. In the method, an LED lamp is used as a light source to provide energy, economical and easily available seconda...
|
|
WO/2023/240791A1 |
Disclosed in the present invention is an environment-friendly preparation method for an N-methylamide compound. An LED lamp is used as a light source to provide energy, an economical and easily available tertiary amide is used as a react...
|
|
WO/2023/236824A1 |
The present application provides a dendron-like lipid compound, a liposome, a lipid complex, and a lipid nanoparticle and a use thereof. The dendron-like lipid compound is selected from any one of structures represented by formulas I-III...
|
|
WO/2023/238930A1 |
Provided are novel compounds which are analogues to be removed from APIs and formulations. Also provided are standard products of analogues to be used in controlling the qualities of medicines. Analogue 1: 3-ethyl-4-\{4-[4-(1-methyl-1H-p...
|
|
WO/2023/240156A1 |
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/234425A1 |
The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
|
|
WO/2023/227757A1 |
The invention provides protected ortho-quinone compounds comprising a group represented by: Formula (I) where -Ar- is optionally substituted phenylene, -X is selected from -NH2, -OH and -SH, and the protected forms of each, -W- is option...
|
|
WO/2023/221851A1 |
Provided is a method for preparing valproamide represented by chemical structural formula I and sodium valproate represented by formula II. The method is characterized in that cyanoacetate and 1-chloropropane are subjected to composite c...
|
|
WO/2023/224095A1 |
This fluorine-containing ether compound is represented by the following formula. R1-R2-CH2-R3[-CH2-R4-CH2-R3]x-CH2-R5-R6 (where R1 and R6 are organic groups having 1-50 carbon atoms, R2 is formula (2-1) or (2-2), R5 is formula (2-3) or (...
|
|
WO/2023/222946A1 |
The present invention relates to a process for the preparation of cabozantinib.
|
|
WO/2023/223885A1 |
The present invention provides a production method for an amide group-containing monomer. With the present invention, an amide group-containing monomer in which the amount of impurities is low is efficiently produced, the production meth...
|
|
WO/2023/224093A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (Where: R1 and R4 are terminal groups which include 2 or 3 polar groups, in which each polar group bonds to a different ca...
|
|
WO/2023/220131A2 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Kα enzymes with the compounds and compositions of the disclosure. The present disclosure further re...
|
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
|
WO/2023/214694A1 |
The present invention relates to a method for separating and recovering acetic acid and dimethylformamide from waste solvent, the method comprising the steps of: introducing a waste solvent containing water, acetic acid, and dimethylform...
|
|
WO/2023/208020A1 |
Disclosed are an intermediate of a polyamine derivative pharmaceutical salt, a preparation method therefor, and use thereof. The intermediate compound has the following structure: (I), which can be used to prepare a polyamine derivative ...
|
